Venous thromboembolism (VTE) is the third most common cause of death worldwide. The
incidence of VTE varies according to different countries, ranging from 1–2 per 1000 person …

Antiphospholipid Syndrome Antiphospholipid antibodies can induce endothelial-cell,
complement, platelet, neutrophil, and monocyte activation, leading to thrombosis, renal …

Patients with COVID-19 are at high risk for thrombotic arterial and venous occlusions. Lung
histopathology often reveals fibrin-based blockages in the small blood vessels of patients …

Background The efficacy and safety of direct oral anticoagulants (DOACs) for patients with
thrombotic antiphospholipid syndrome remain controversial. Objectives The authors …

Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by
circulating autoantibodies that recognize cell surface phospholipids and phospholipid …

The antiphospholipid syndrome (APS) is characterized by thrombosis and/or pregnancy
morbidity in the presence of antiphospholipid antibodies, including anti-β2-glycoprotein-I …

The antiphospholipid syndrome is a prothrombotic disorder associated with autoantibodies.
It is associated with obstetrical complications (mainly spontaneous abortion) as well as …

Currently, we use the classification criteria for antiphospholipid syndrome (APS) formulated
during the consensus conference in Sapporo and revised in Sydney 1. Classification criteria …

Background Many studies reported high prevalence of antiphospholipid antibodies (aPL) in
patients with COVID-19 raising questions about its true prevalence and its clinical impact on …

Deep vein thrombosis (DVT) is a major health problem that requires improved prophylaxis
and treatment. Inflammatory conditions such as infection, cancer, and autoimmune diseases …